Among the 16 LC patients, 12 were EGFR-positive and had progressed on EGFR tyrosine kinase inhibitor (TKI) therapy (75.0%) and four were EGFR/ALK-negative and treatment-naïve (25.0%; Table 2). Here, ALK is linked to laryngotracheoesophageal cleft.